Last checked at 3 Feb 2022 11:10
Avacta shares up 12% after chemotherapy drug advances to next stage
Avacta shares up 12% after chemotherapy drug advances to next stage
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Avacta Group Share News (AVCT)
AVCT Share
Price
AVCT Share
News
AVCT Share
Chat143
AVCT Share
Trades365
AVCT
Live RNS2
AVCT Share
Charts
AVCT Level 2
Console
AVCT Live
Share Price
AVCT Broker
Ratings
AVCT Directors
Deals
AVCT Financial
Diary
AVCT
Fundamentals
AVCT Short
Positions1
AVCT
Media
Avacta Group Information
Share Price Information for Avacta Group (AVCT)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
48.50
Bid:
48.00
Ask:
49.00
Change:
3.80 (8.44%)
Spread:
1.00 (2.083%)
Open:
45.00
High:
48.80
Low:
45.60
Prev. Close:
45.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.18 Jan 2022 14:36
Avacta Group selects second pro-drug candidate
(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Tuesday that the next 'preCISION' drug candidate, 'AVA3996', had been selected for preclinical development, with a view to a first-in-human phase one clinical trial from the second half of 2023.
Read more18 Jan 2022 13:52
Avacta selects potential tumour treatment for preclinical development
Avacta selects potential tumour treatment for preclinical development
Read more18 Jan 2022 10:58
AIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers
AIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers
Read more10 Jan 2022 12:16
LONDON MARKET MIDDAY: Stocks slip as investors brace for Fed testimony
LONDON MARKET MIDDAY: Stocks slip as investors brace for Fed testimony
Read more10 Jan 2022 12:08
Abingdon Health plunges after Avacta stops selling Covid-19 test
Abingdon Health plunges after Avacta stops selling Covid-19 test
Read more10 Jan 2022 11:29
AIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests
AIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests
Read more10 Jan 2022 11:05
Shares plummet as Avacta pauses sale of lateral flow tests
(Sharecast News) - Avacta Group has suspended sales of its antigen lateral flow tests, causing the AIM-listed firm's share price to plummet.
Read more10 Jan 2022 09:20
Avacta shares drop as Covid tests show reduced sensitivity to Omicron
Avacta shares drop as Covid tests show reduced sensitivity to Omicron
Read more22 Dec 2021 12:21
LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures
LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures
Read more22 Dec 2021 11:28
AIM WINNERS & LOSERS: BlueRock hit by Covid; D4T4 up on contract wins
AIM WINNERS & LOSERS: BlueRock hit by Covid; D4T4 up on contract wins
Read more22 Dec 2021 10:31
Avacta shares up as flow tests receive CE mark for self-test use
Avacta shares up as flow tests receive CE mark for self-test use
Read more15 Dec 2021 11:56
Avacta confirms lateral flow tests can detect Omicron variant
Avacta confirms lateral flow tests can detect Omicron variant
Read more15 Dec 2021 08:24
Avacta antigen lateral flow test shown to detect Omicron
(Sharecast News) - Aim-listed Avacta said on Wednesday that its AffiDX® antigen lateral flow test has been shown to detect the Omicron variant of the SARS-CoV-2 virus in clinical samples.
Read more29 Nov 2021 11:07
IN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US
IN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US
Read more